• Home
  • News
  • Stephenson Harwood advises capiton on KD Pharma single-asset secondary

09 Dec 2019

Stephenson Harwood advises capiton on KD Pharma single-asset secondary


Law firm Stephenson Harwood LLP has advised private equity firm capiton on a general partner-led single asset secondary transaction relating to the KD Pharma Group.

KD Pharma Group is a producer of omega-3 ingredients for pharmaceutical and nutraceutical products. It was acquired by capiton IV fund in 2013 and has grown from a single-digit revenue business to one of the industry’s largest players. 

capiton initiated a GP-led single-asset secondary transaction to provide KD Pharma with the necessary duration and follow-on capital to finance the Group’s future growth potential. The oversubscribed transaction enabled capiton to successfully close the fundraising for its new single-asset continuation fund and gave existing partners an early liquidity option to either sell their stake or to remain (partially or fully) invested in KD Pharma. Under the new fund structure capiton will continue to manage its portfolio company KD Pharma for further growth as general partner. 

The Stephenson Harwood team was led by partner Gabriel Boghossian with support from associates Victoria Silver and Marina Pappas. The team co-advised capiton alongside CMS Hasche Sigle and P+P Pöllath + Partners. The financial advisor was PJT Park Hill. 



Gabriel Boghossian

Gabriel Boghossian
Partner and head of our secondaries practice

T:  +44 20 7809 2762 M:  Email Gabriel | Vcard Office:  London

Victoria Silver

Victoria Silver
Managing associate

T:  +44 20 7809 2190 M:  Email Victoria | Vcard Office:  London


Andrew Rieley
Head of Communications & PR
T: +44 20 7809 2886
Email Andrew